Q-State Biosciences
About Q-State Biosciences
Q-State Biosciences has developed an all-optical electrophysiology platform for controlling and recording activity in electrically active cells: primary and human iPSC-derived cardiomyocytes and neurons. The platform combines proprietary ultrasensitive optogenetic actuators, genetically encoded voltage indicators, stem cell technology and advanced optical imaging. Q-State Biosciences uses custom instrumentation and software to probe cellular physiology with sub-micron spatial resolution and sub-millisecond temporal resolution. Q-State technology probes dynamic cellular physiology with far higher throughput and information content than are achieved with manual patch clamp, multi electrode arrays, or calcium- or voltage-sensitive dyes.
Company Metrics
- Employees: 11-50
- Monthly Visits: None
- Tech Stack: 17 active products
Financial Information
- Estimated Revenue: $1M to $10M
- Total Funding: 22518527 USD
- Last Funding: 1300000 USD (Grant)
- Funding Status:
Technology Stack
Q-State Biosciences actively uses 17 products in their tech stack.
Market Presence
Industries: Biotechnology, Health Care, Life Science, Pharmaceutical
Headquarters: Cambridge, Massachusetts, United States
Leadership
- Paul Medeiros - President and Chief Executive Officer LinkedIn
Employees
- Chris Watt - Chief Financial Officer (LinkedIn)
- Graham Dempsey - Chief Scientific Officer (LinkedIn)
- Owen McManus - Chief Technology Officer (LinkedIn)